The U.S. Food and Drug Administration (FDA) awarded a $19,731,473.00 definitive contract to Zata Pharmaceuticals, Inc. for the development and maintenance of FDA-ARGOS 2 universal closed systems for pathogen reduction in donated whole blood units. This contract, awarded on September 27, 2021, has a completion date of September 26, 2025 and does not have a set-aside designation. The contract was issued under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas of regulatory science to support the agency's mission. This contract aims to advance scientific knowledge and modernize regulatory science in the area of evaluating emerging technologies for pathogen reduction in blood products.
Generated 9/20/24, 9:12 AM